• Significant expansion of product roll-out into one of the biggest life science markets in Europe
• OZYME is a leading life science distributor focused on molecular biology and cell biology
• Fifth distribution agreement signed in just three months
Madrid, Spain and Heidelberg, Germany, March 10, 2015 – SYGNIS AG (Frankfurt: LIO1; ISIN: DE000A1RFM03; Prime Standard) today announced that it has signed a non-exclusive distribution agreement for its proprietary TruePrime™ product line with OZYME for France, one of the biggest life science markets in Europe.
Under the terms of the agreement, SYGNIS has granted OZYME the non-exclusive rights to promote, market and sell the existing and all future TruePrime™ products to scientists working in the wide field of molecular biology throughout France. TruePrime™ products are based on the combination of the recently discovered DNA primase “TthPrimPol” and the Phi29 polymerase, which allows the amplification of total genomic DNA from smallest amounts of samples down to single cells without the need of random synthetic primers.
OZYME is a specialist provider offering a broad portfolio of innovative research reagents and state-of-the-art instruments in the field of molecular biology as well as cell biology applications to customers in France.
"We are pleased to announce the distribution agreement for an important European key market such as France,” Pilar de la Huerta, CEO and CFO of SYGNIS commented. “OZYME complements our fast growing list of leading international distribution partners. This is the fifth non-exclusive distribution agreement signed by SYGNIS in three months. It proves the ongoing interest and demand in our TruePrime™ product and technology family."
About TruePrime™
TruePrime™ is the brand name of a revolutionary novel multiple displacement amplification (MDA) technology and one of the key products in SYGNIS’ portfolio. TruePrime™ is based on the combination of the recently discovered DNA primase “TthPrimPol” and the extremely processive and high-fidelity Phi29 polymerase to amplify uniformly total genomic DNA for a multitude of applications including next generation sequencing and single cell analysis. The extraordinary strand-displacement capacity of Phi29 polymerase allows TthPrimPol to generate new primers on the displaced strands that are extended by Phi29 DNA pol, resulting in exponential isothermal DNA amplification without the need of any synthetic random primers.
The resulting benefits of this innovative approach are enormous and include the complete absence of common artifacts linked to the use of oligonucleotides, a reduced amplification bias in genome coverage compared to methods using random synthetic primers, a surpassing reliability as contaminating DNA is not amplified and an exquisite reproducibility when DNA is amplified from single mammalian cells. Moreover, TruePrime™ shows superior sensitivity, is easy to use and works perfectly well with all commonly used NGS platforms such as Illumina and Ion Torrent.
For further information please contact:
SYGNIS AG
Pilar de la Huerta
CEO/CFO
Phone: +34 91 192 36 50
Email: pdelahuerta@sygnis.com
MC Services AG
Raimund Gabriel
Managing Partner
Phone: +49 89 210228 30
Email: raimund.gabriel@mc-services.eu
About SYGNIS AG: www.sygnis.com
Following the merger with X-Pol Biotech in 2012, SYGNIS specializes on the development and commercialization of products for DNA amplification and sequencing. SYGNIS AG, listed at the German Stock Exchange (Prime Standard segment, Tick: LIO1; ISIN: DE000A1RFM03), has a commercial product for whole genome DNA amplification, SensiPhi ® , licensed to an industry leading partner and is currently developing its own TruePrime™ product line based on its proprietary TruePrime™ technology for use in the fast growing field of Next Generation Sequencing. The first products for single cell as well as whole genome DNA amplification were launched beginning 2015.
Help employers find you! Check out all the jobs and post your resume.
• OZYME is a leading life science distributor focused on molecular biology and cell biology
• Fifth distribution agreement signed in just three months
Madrid, Spain and Heidelberg, Germany, March 10, 2015 – SYGNIS AG (Frankfurt: LIO1; ISIN: DE000A1RFM03; Prime Standard) today announced that it has signed a non-exclusive distribution agreement for its proprietary TruePrime™ product line with OZYME for France, one of the biggest life science markets in Europe.
Under the terms of the agreement, SYGNIS has granted OZYME the non-exclusive rights to promote, market and sell the existing and all future TruePrime™ products to scientists working in the wide field of molecular biology throughout France. TruePrime™ products are based on the combination of the recently discovered DNA primase “TthPrimPol” and the Phi29 polymerase, which allows the amplification of total genomic DNA from smallest amounts of samples down to single cells without the need of random synthetic primers.
OZYME is a specialist provider offering a broad portfolio of innovative research reagents and state-of-the-art instruments in the field of molecular biology as well as cell biology applications to customers in France.
"We are pleased to announce the distribution agreement for an important European key market such as France,” Pilar de la Huerta, CEO and CFO of SYGNIS commented. “OZYME complements our fast growing list of leading international distribution partners. This is the fifth non-exclusive distribution agreement signed by SYGNIS in three months. It proves the ongoing interest and demand in our TruePrime™ product and technology family."
About TruePrime™
TruePrime™ is the brand name of a revolutionary novel multiple displacement amplification (MDA) technology and one of the key products in SYGNIS’ portfolio. TruePrime™ is based on the combination of the recently discovered DNA primase “TthPrimPol” and the extremely processive and high-fidelity Phi29 polymerase to amplify uniformly total genomic DNA for a multitude of applications including next generation sequencing and single cell analysis. The extraordinary strand-displacement capacity of Phi29 polymerase allows TthPrimPol to generate new primers on the displaced strands that are extended by Phi29 DNA pol, resulting in exponential isothermal DNA amplification without the need of any synthetic random primers.
The resulting benefits of this innovative approach are enormous and include the complete absence of common artifacts linked to the use of oligonucleotides, a reduced amplification bias in genome coverage compared to methods using random synthetic primers, a surpassing reliability as contaminating DNA is not amplified and an exquisite reproducibility when DNA is amplified from single mammalian cells. Moreover, TruePrime™ shows superior sensitivity, is easy to use and works perfectly well with all commonly used NGS platforms such as Illumina and Ion Torrent.
For further information please contact:
SYGNIS AG
Pilar de la Huerta
CEO/CFO
Phone: +34 91 192 36 50
Email: pdelahuerta@sygnis.com
MC Services AG
Raimund Gabriel
Managing Partner
Phone: +49 89 210228 30
Email: raimund.gabriel@mc-services.eu
About SYGNIS AG: www.sygnis.com
Following the merger with X-Pol Biotech in 2012, SYGNIS specializes on the development and commercialization of products for DNA amplification and sequencing. SYGNIS AG, listed at the German Stock Exchange (Prime Standard segment, Tick: LIO1; ISIN: DE000A1RFM03), has a commercial product for whole genome DNA amplification, SensiPhi ® , licensed to an industry leading partner and is currently developing its own TruePrime™ product line based on its proprietary TruePrime™ technology for use in the fast growing field of Next Generation Sequencing. The first products for single cell as well as whole genome DNA amplification were launched beginning 2015.
Help employers find you! Check out all the jobs and post your resume.
